Ireland - English - HPRA (Health Products Regulatory Authority)

genthon b.v. - sevelamer carbonate anhydrous - film-coated tablet - 800 milligram(s) - drugs for treatment of hyperkalemia and hyperphosphatemia; sevelamer

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sevelamer carbonate, quantity: 800 mg - tablet, film coated - excipient ingredients: silicon dioxide; hyprolose; crospovidone; mannitol; zinc stearate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; purified talc; xanthan gum; polyvinyl alcohol; lecithin - sevelamer lupin is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic kidney disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sevelamer carbonate, quantity: 800 mg - tablet, film coated - excipient ingredients: hyprolose; crospovidone; silicon dioxide; mannitol; zinc stearate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; purified talc; xanthan gum; polyvinyl alcohol; lecithin - arx-sevelamer is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic kidney disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - citalopram hydrobromide’ - film coated tablet - 40 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - citalopram hydrobromide’ - film coated tablet - 40 milligram

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaforte (malaysia) sdn. bhd. - citalopram hydrobromide -

European Union - English - EMA (European Medicines Agency)

sanofi b.v. - sevelamer carbonate - hyperphosphatemia; renal dialysis - all other therapeutic products - renvela is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l.renvela should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.